Larimar Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Larimar Therapeutics, Inc. on May 21, 2021. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock and pre-funded warrants.
- Securities Issued: 4,479,192 shares of Common Stock and pre-funded warrants to purchase 2,616,856 shares.
- Offering Price: $13.43 per share of Common Stock; $13.42 per share underlying Pre-Funded Warrants.
- Expected Gross Proceeds: Approximately $95.3 million (before offering expenses and warrant exercise prices).
- Use of Proceeds: Clinical development of CTI-1601, additional research and development, working capital, and general corporate purposes.
- Expected Closing Date: On or about May 25, 2021.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with certain investors. Additionally, upon closing, the Company will execute a Registration Rights Agreement requiring the filing of a Form S-3 registration statement within 30 days. Failure to meet this deadline may result in liquidated damages. An Amended and Restated Registration Rights Agreement will also be executed to include securities purchased by the Deerfield Funds.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected closing and use of proceeds. Key risks include the inability of the Company or Purchasers to satisfy closing conditions. The securities are unregistered and may not be resold in the U.S. absent registration or an exemption. The Pre-Funded Warrants are immediately exercisable at $0.01 per share but are subject to beneficial ownership limitations (4.985% or 9.99%).
Investor Verification Checklist
- Confirm the actual closing date and final gross proceeds once the transaction is completed.
- Verify the filing of the Form S-3 registration statement within the 30-day deadline to avoid liquidated damages.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific investor representations and conditions.
- Monitor the dilution impact of the 4,479,192 shares and 2,616,856 pre-funded warrants on existing shareholders.
- Check subsequent filings for updates on the clinical development progress of CTI-1601 funded by these proceeds.